Who are UFT adjuvant chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Erlotinib, Pemetrexed, Phthalin, Irinotecan, 5FU, leucovorin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/uft-adjuvant-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

UFT adjuvant chemotherapy — Competitive Intelligence Brief

UFT adjuvant chemotherapy (UFT adjuvant chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite chemotherapy. Area: Oncology.

phase 3 Antimetabolite chemotherapy Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

UFT adjuvant chemotherapy (UFT adjuvant chemotherapy) — Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. UFT is a combination of uracil and tegafur (a prodrug of fluorouracil) that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
UFT adjuvant chemotherapy TARGET	UFT adjuvant chemotherapy	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	phase 3	Antimetabolite chemotherapy	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Erlotinib, Pemetrexed	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes
Phthalin	PHENOLPHTHALEIN		marketed	phenolphthalein	Thymidylate synthase, Thymidylate synthase
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite chemotherapy class)

Hoffmann-La Roche · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). UFT adjuvant chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/uft-adjuvant-chemotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab